October 25, 2023
Via: Pharma TimesThe US Food and Drug Administration (FDA) has granted clearance for Endogena Therapeutics’ investigational new drug application to treat geographic atrophy (GA), an advanced form of age-related macular degeneration (AMD). The FDA clearance will enable Endogena to progress with the […]
Clinical Trials, Research and Development
November 18, 2022
Via: GENA new study from New York Eye and Ear Infirmary of Mount Sinai demonstrates that patients with a specific form of age-related macular degeneration (AMD) may have either underlying heart damage from heart failure and heart attacks, or advanced heart […]
October 29, 2021
Via: Biopharm InternationalGenentech, a member of the Roche Group, announced on Oct. 22nd, 2021, that FDA had approved Susvimo (100 mg/mL ranibizumab injection) for the treatment of wet, or neovascular, age-related macular degeneration (AMD), a condition that can lead to rapid and […]
September 22, 2021
Via: European Pharmaceutical ReviewNovartis have announced that it has acquired Arctos Medical, adding a pre-clinical optogenetics-based Adeno-associated viruses (AAV) gene therapy programme and Arctos’ proprietary technology to its ophthalmology portfolio. The acquisition aims to more efficiently develop treatments for patients with vision loss […]
Cell and Gene Therapy, Industry
December 2, 2020
Via: FierceBiotechJanssen is tapping little-known and privately held Hemera Biosciences for a new gene therapy aimed at reversing a severe disease. The deal, financials of which are not being shared, is for the investigational phase 1 gene therapy HMR59, which is […]
July 19, 2024
July 11, 2024
July 11, 2024
Copyright © 2024. All rights reserved
